RIGEL PHARMACEUTICALS INC RIGL revenue by segment, product and geography
In its fiscal year ending 2025-12-31, RIGEL PHARMACEUTICALS INC reported revenue across 1 business segments; the largest, Single Reportable Segment, was $294M, 100.0% of the filed sum (+64.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Single Reportable Segment$294M100.0%+64.1% yoy
Members sum to the consolidated $294M for this period.
- Gross Product$310Mshare n/a+47.7% yoy
- Product$232Mshare n/a+60.1% yoy
- Discounts And Allowances-$78Mshare n/a+19.9% yoy
- Contract Revenues From Collaborations$62Mshare n/a+80.5% yoy
- Release Of Share Cost Liability$40Mshare n/ano prior
- Royalty Delivery Of Drug Supplies And Others$19.1Mshare n/a-6.5% yoy
- Development Milestones$3Mshare n/ano prior
- Government Contract$265Kshare n/ano prior
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- One Operating Segment$58.8M100.0%+10.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.